Edesa Biotech (EDSA) vs ImageneBio (IMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Edesa Biotech (EDSA) has outperformed ImageneBio (IMA) over the past year, gaining 34.6% versus a loss of 48.5%. Over five years, EDSA leads with a -93.3% price change compared with -97.1% for IMA. ImageneBio is the larger company by market cap ($48.7 million vs $47.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDSA | IMA |
|---|---|---|
| Share price | $3.54 | $4.28 |
| Market cap | $47.76M | $48.68M |
| 1-day change | -3.42% | +0.47% |
| YTD return | +157.75% | -38.26% |
| 1-year return | +34.56% | -48.49% |
| 5-year return | -93.31% | -97.07% |
| EPS (TTM) | $-1.72 | $-4.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.32 | $9.10 |
| 52-week low | $0.72 | $3.94 |
| Distance from 52-week high | -82.60% | -52.97% |
| Analyst consensus | none | none |
| Avg. price target upside | +361.95% | +320.56% |
| Average volume | 61.89K | 13.04K |
| Shares outstanding | 13.51M | 11.37M |
| Employees | 17 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDSA has outperformed IMA by 83.0 percentage points over the past year.
About Edesa Biotech
EDSA stock →Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
About ImageneBio
IMA stock →ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
EDSA vs IMA FAQ
Which is bigger, Edesa Biotech or ImageneBio?
ImageneBio (IMA) is larger, with a market capitalization of $48.68M compared with $47.76M for Edesa Biotech (EDSA).
Which stock has performed better over the past year, EDSA or IMA?
EDSA returned +34.56% over the past 12 months, compared with -48.49% for IMA (price return, excluding dividends). Past performance does not predict future results.
Are Edesa Biotech and ImageneBio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Edesa Biotech and Biotechnology: Biological Products (No Diagnostic Substances) for ImageneBio.